What is the short‑term and long‑term treatment for ocular myasthenia gravis?

Treatment of Ocular Myasthenia Gravis

Short-Term Treatment (Initial Management)

Start with pyridostigmine 30 mg orally three times daily and titrate gradually to a maximum of 120 mg four times daily as tolerated, recognizing that approximately 50% of ocular myasthenia patients will show minimal response to pyridostigmine alone and will require escalation to corticosteroids. 1, 2

First-Line Therapy: Pyridostigmine

• Initiate pyridostigmine at 30 mg orally three times daily 1, 2, 3
• Gradually increase the dose based on symptom response, up to a maximum of 120 mg four times daily 1, 2
• Expect limited efficacy in ocular disease—only about 50% of patients with purely ocular symptoms achieve adequate control with pyridostigmine monotherapy 1, 2, 4
• Monitor for cholinergic side effects including excessive salivation, tearing, diarrhea, and abdominal cramping 4

Second-Line Therapy: Corticosteroids

If pyridostigmine fails to control symptoms adequately, escalate to oral prednisone 1–1.5 mg/kg/day, which produces favorable responses in 66–85% of patients. 1, 2

• Start prednisone at 1–1.5 mg/kg orally daily (or use alternate-day regimen) 1, 2, 3
• Critical pitfall: Increase steroid doses slowly to avoid precipitating myasthenic crisis during the initial weeks of treatment 4, 3
• After achieving maximum therapeutic benefit, taper gradually to the lowest effective maintenance dose 4, 3
• Corticosteroids demonstrate clinical efficacy in 66–85% of myasthenia gravis patients 1, 2

---

Long-Term Treatment (Maintenance & Prevention of Generalization)

For long-term management, add azathioprine as a steroid-sparing agent when high-dose corticosteroids are required or when attempting to minimize chronic steroid exposure, as early immunosuppressive treatment reduces the risk of progression to generalized disease from the typical 50–70% down to approximately 12%. 1, 2, 5

Steroid-Sparing Immunosuppression

• Azathioprine is the preferred third-line agent when steroid response is inadequate or to reduce long-term corticosteroid burden 1, 2, 3
• Mycophenolate mofetil represents an alternative steroid-sparing option with demonstrated efficacy 6, 7
• These agents allow tapering of corticosteroid doses while maintaining symptom control 4, 3

Prevention of Generalization

Early immunosuppressive treatment (corticosteroids and/or azathioprine) dramatically reduces the risk of progression to generalized myasthenia gravis. 5, 3

• Without immunosuppressive treatment, approximately 50–80% of patients with initial ocular symptoms progress to generalized disease within a few years, most commonly within the first two years 1, 2, 5
• With early immunosuppressive therapy, the conversion rate drops to approximately 12% 5
• In untreated or late-treated patients, the generalization rate reaches 64%, compared to only 12% in those receiving early immunosuppression 5
• 50% of patients who generalize do so within two years, and 75% within four years of onset 5

Thymectomy Considerations

• Thymectomy is mandatory when thymoma is identified on chest CT imaging (present in 10–20% of AChR-positive patients) 1, 2, 5
• For ocular myasthenia without thymoma, thymectomy remains controversial and is not routinely recommended 4, 5, 3
• When performed in selected cases, thymectomy correlates with good outcomes but shows no clear advantage over medical treatment alone 5

---

Monitoring and Follow-Up

• Serial pulmonary function testing (negative inspiratory force and vital capacity) is essential in all patients, as dysphagia and bulbar weakness precede myasthenic crisis in more than 50% of cases 1, 2
• Regular assessment for progression to generalized symptoms, particularly within the first two years 1, 5
• Screen for concurrent autoimmune conditions including thyroid disease, systemic lupus erythematosus, and rheumatoid arthritis 1, 7

---

Medications to Avoid

Immediately discontinue and permanently avoid β-blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics, as these agents can precipitate myasthenic crisis. 1, 2, 8

---

Adjunctive Non-Pharmacologic Options

• Occlusive devices (eye patches) for diplopia 4
• Prisms for mild ocular misalignment 4
• Eyelid crutches or supports for ptosis 4
• Topical agents for mild to moderate ptosis 4
• Strabismus surgery or eyelid elevation surgery only in long-standing, stable cases 4

---

Treatment Algorithm Summary

1. Start: Pyridostigmine 30 mg TID, titrate to 120 mg QID 1, 2, 3
2. If inadequate response (expected in ~50%): Add prednisone 1–1.5 mg/kg/day (increase slowly) 1, 2, 4
3. For long-term control: Add azathioprine as steroid-sparing agent 1, 2, 3
4. If thymoma present: Proceed to thymectomy 1, 2, 5
5. Monitor continuously: Pulmonary function, progression to generalized disease 1, 2

The evidence strongly supports early, aggressive immunosuppressive treatment to prevent the high rate of generalization seen in untreated ocular myasthenia. 5, 3